Workflow
TIANSHAN BIO(300313)
icon
Search documents
天山生物(300313) - 2015 Q3 - 季度财报
2015-10-23 16:00
Financial Performance - Total operating revenue reached CNY 110,800,432.47, a significant increase of 324.86% year-on-year[7] - Net profit attributable to shareholders was a loss of CNY 4,087,767.96, representing a decline of 352.41% compared to the same period last year[7] - The company reported an operating loss of CNY -19,384,306.66, a decline of 747.24% from an operating profit of CNY 2,994,918.35 in the previous year[23] - The net profit attributable to the parent company was CNY -14,219,457.54, a decrease of 327.67% from CNY 6,245,627.91 in the previous year[23] - The company reported a significant increase in prepayments, which rose to CNY 123,585,460.43 from CNY 826,122.50, indicating a substantial growth[51] - The company reported a comprehensive income total of -¥32,295,051.30 for the current period, contrasting with ¥6,866,821.39 in the previous period[68] Assets and Liabilities - Total assets increased by 35.85% to CNY 828,674,123.48 compared to the end of the previous year[7] - Total liabilities increased to CNY 392,187,809.89 from CNY 173,575,443.57, showing a growth of approximately 126.5%[53] - The company's equity attributable to shareholders decreased to CNY 370,212,687.14 from CNY 395,245,973.90, a decline of about 6.3%[54] - Current assets totaled CNY 462,136,494.91, up from CNY 308,823,511.38, indicating a rise of about 49.5%[51] - The company's long-term investments decreased from CNY 197,084,180.00 to CNY 159,434,180.00, reflecting a decline of approximately 19.1%[55] Cash Flow - The net cash flow from operating activities showed a drastic improvement, with a negative value of CNY 131,980,825.94, reflecting a 2,991.20% change from the previous year[7] - Cash inflow from financing activities increased by 242.68% to 251.25 million yuan, primarily due to increased bank loans[28] - The net cash flow from operating activities was -131,980,825.94 CNY, a significant decline compared to -4,269,563.86 CNY in the previous period, indicating a worsening operational performance[74] - The total cash outflow from operating activities was 342,143,392.52 CNY, compared to 190,280,577.66 CNY in the previous period, indicating increased operational costs[74] Revenue Sources - Sales revenue from breeding livestock amounted to 82.23 million yuan, up 1063.28% year-on-year, while meat product sales revenue increased by 207.36% to 18.08 million yuan[27] - The proportion of breeding livestock sales in total revenue rose by 40.8 percentage points to 50.99%[28] - The company experienced a 53.38% decrease in government subsidies recognized as non-operating income[28] Investments and Acquisitions - The company completed the acquisition of Mingahai Ranch assets in Victoria, Australia, positioning it as a breeding base, aiming to enhance profitability and market layout[14] - The project for bull semen production and research has received CNY 4,152.15 million, with CNY 1,546.24 million invested in the current period, achieving 52.98% of the planned progress[35] - The acquisition of Australian assets has been fully completed with a total investment of CNY 5,294.33 million, achieving 100% of the planned investment[35] Risk Management - The company faces risks related to seasonal fluctuations in revenue due to reliance on government procurement for sales[12] - The company emphasizes risk management in overseas investments, particularly regarding policy changes and market conditions[14] - The company is aware of exchange rate risks due to fluctuations in the AUD/CNY exchange rate and is taking measures to mitigate these risks[15] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,092[17] - The company holds a 30.00% stake (56,080,000 shares) in the top shareholder, Tianshan Animal Husbandry Development Co., Ltd., with 26,210,996 shares pledged[18] - The chairman and senior management increased their shareholding by a total of 922,900 shares, raising their collective ownership from 1.88% to 2.37%[47] Future Plans - The company plans to expand its market share through product line diversification and vertical integration of the industry chain[10] - The company plans to enhance internal controls and performance evaluation mechanisms to mitigate management risks[14] - The company plans to accelerate live cattle introduction and capitalize on the winter sales peak for beef and lamb products in the fourth quarter[28]
天山生物(300313) - 2015 Q2 - 季度财报
2015-08-17 16:00
Financial Performance - Total revenue for the reporting period was ¥50,459,891.29, an increase of 17.07% compared to ¥43,102,329.00 in the same period last year[18]. - Net profit attributable to ordinary shareholders was -¥10,131,689.58, a decrease of 319.01% from ¥4,626,124.52 in the previous year[18]. - Net cash flow from operating activities was -¥133,077,592.74, a significant decline of 16,967.06% compared to ¥788,978.99 in the same period last year[18]. - The weighted average return on equity was -2.61%, down 3.76% from 1.15% in the previous year[18]. - The company reported a significant decline in basic and diluted earnings per share, both at -¥0.0557, a decrease of 319.29% from ¥0.0254[18]. - The company reported a net loss of ¥14,028,023.85, a decrease of 398.61% compared to a net profit of ¥4,697,795.77 in the previous year[44]. - The total comprehensive income for the first half of 2015 was a loss of CNY 21,640,916.74, contrasting with a profit of CNY 4,697,795.77 in the previous year[153]. Assets and Liabilities - Total assets at the end of the reporting period were ¥724,691,874.34, representing an 18.80% increase from ¥610,012,373.40 at the end of the previous year[18]. - Total liabilities increased to CNY 277,551,426.25 from CNY 173,575,443.57, indicating a growth of about 60.0%[144]. - The company's equity increased significantly, with total equity reaching CNY 447,140,448.09, up from CNY 436,436,929.83, showing a growth of approximately 2.0%[144]. - The total owner's equity at the end of the reporting period is 405,101,619.68 CNY, showing a decrease from the previous period's 412,841,069.69 CNY[179]. Revenue Sources - The revenue from imported frozen semen increased significantly, accounting for 41.34% of total revenue, up 14.95 percentage points year-on-year[46]. - The sales volume of imported frozen semen increased by 89.04%, contributing to a revenue growth of ¥9,485,221.47, or 83.39%[38]. - The sales volume of milk increased by 22.52%, but the sales price decreased by 16.32%, leading to a 1.57 percentage point drop in its revenue share[46]. Costs and Expenses - Operating costs rose to ¥30,568,793.55, reflecting a year-on-year increase of 28.54%[36]. - Selling expenses surged by 61.10% to ¥9,529,729.32, attributed to increased market development efforts for imported frozen semen[36]. - Financial expenses skyrocketed by 323.87% to ¥3,564,754.71 due to new project investments leading to increased bank borrowings[37]. - Research and development expenses increased by 66.42% to ¥1,714,075.00, driven by investments in genetic testing systems and databases[37]. Strategic Initiatives - The company plans to expand its product line and market share through investments, collaborations, and market expansion strategies[24]. - The company is implementing measures to mitigate performance risks, including enhancing production management and cost control[24]. - The company plans to continue expanding its market for imported frozen semen and enhance its breeding services[38]. - The company aims to enhance its breeding business's core competitiveness through the establishment of a descendant evaluation database[51]. Fundraising and Investments - The company has begun implementing fundraising projects, but uncertainties remain regarding their completion and expected returns[26]. - The company has a remaining balance of RMB 7,460.60 million in its fundraising account as of June 30, 2015[65]. - The company has invested a total of RMB 6,602.94 million from its fundraising efforts during the reporting period, with a cumulative investment of RMB 19,966.92 million[64]. - The total amount raised from the IPO was CNY 295.49 million, with a net amount of CNY 260.9982 million after deducting various issuance costs[68]. Shareholder and Equity Information - The company reported a total of CNY 2.96 million in related party transactions, which accounted for 0.26% of the total transaction amount[95]. - The total number of shares increased from 90,910,000 to 186,951,000 due to a cash dividend of RMB 0.50 per 10 shares and a capital reserve conversion of 10 shares for every 10 shares held[123]. - The company has a total of 2,931,000 shares under incentive restrictions for other 62 incentive objects excluding senior management[132]. - The company has not proposed any cash dividend distribution or stock bonus for the half-year period[85]. Market and Industry Outlook - The beef market is expected to grow, with per capita beef consumption projected to increase from 5.19 kg in 2015 to 5.49 kg by 2020[55]. - National policies are increasingly supportive of the livestock industry, providing a favorable environment for the company's growth and market expansion[53]. - The total beef consumption in China increased from 513,000 tons in 2000 to 796,000 tons in 2020, with an average annual growth rate of 2.00% from 2010 to 2015 and 2015 to 2020[57]. Compliance and Governance - The financial statements comply with the requirements of the accounting standards, accurately reflecting the company's financial position, operating results, and cash flows[188]. - The company has not engaged in any entrusted financial management or derivative investments during the reporting period[77]. - The company has ensured that the disclosure of raised funds aligns with actual usage, with no violations reported[71].
天山生物(300313) - 2015 Q1 - 季度财报
2015-04-21 16:00
Financial Performance - Total revenue for Q1 2015 was CNY 17,823,490.78, an increase of 24.09% compared to CNY 14,363,265.86 in the same period last year[8] - Net profit attributable to shareholders was CNY -8,095,342.11, a significant decrease of 10,973.60% from CNY 74,449.51 in the previous year[8] - Basic and diluted earnings per share were both CNY -0.0890, a decline of 11,225.00% compared to CNY 0.0008 in the previous year[8] - The company's net profit for Q1 2015 was -9,115,063.07 yuan, a decrease of 9,408.95% compared to the same period last year[26] - Operating profit for the same period was -9,746,485.44 yuan, reflecting a significant increase in expenses due to ongoing investments in beef cattle and breeding operations[26] - The company reported a comprehensive loss of CNY 17,537,216.74 for the quarter, contrasting with a comprehensive income of CNY 97,917.21 in the same quarter last year[66] Cash Flow - Net cash flow from operating activities was CNY -92,360,485.91, down 1,725.80% from CNY 5,680,915.77 in the same period last year[8] - Cash inflows from operating activities totaled CNY 23,934,199.63, a decrease from CNY 67,715,461.81 in the same period last year[71] - The net cash flow from operating activities was -92,360,485.91 CNY, a significant decrease compared to 5,680,915.77 CNY in the previous period[72] - Cash inflow from financing activities increased by 541.30% to 64.90 million yuan, primarily due to an increase in short-term borrowings[27] - The net cash flow from financing activities was 48,405,255.77 CNY, a significant increase from 9,624,106.53 CNY year-over-year[73] Assets and Liabilities - Total assets at the end of the reporting period were CNY 660,017,544.96, an increase of 8.20% from CNY 610,012,373.40 at the end of the previous year[8] - The company's total liabilities reached CNY 204,295,226.29, compared to CNY 173,575,443.57 at the beginning of the year, showing an increase of about 17.7%[58] - The equity attributable to shareholders decreased to CNY 382,667,962.97 from CNY 395,245,973.90, a decline of approximately 3.2%[59] - The company's cash and cash equivalents decreased to CNY 143,045,096.54 from CNY 182,578,621.22, representing a decline of approximately 21.7%[56] Operational Costs - Operating costs increased by 49.84% year-on-year, totaling 12.16 million yuan, leading to a total profit of -8.78 million yuan, a decline of 6,591.72%[28] - The company reported a significant increase in prepayments, which rose to CNY 29,276,826.59 from CNY 826,122.50, indicating a growth of over 3,400%[56] - The overall sales cost of frozen semen increased by 198.12%, leading to a 28 percentage point decline in gross profit margin[29] Strategic Plans and Risks - The company plans to improve performance by expanding self-produced frozen semen sales and actively exploring the imported frozen semen market[12] - The company faces risks including policy changes regarding quality seed subsidies and potential outbreaks of animal diseases affecting production[12] - The company is facing risks related to fundraising investment projects due to uncertainties in market conditions, which may affect the timely completion and smooth implementation of projects[35] - The company expects stable support from government subsidy policies for high-quality dairy cattle, which may impact future operations if these policies change[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 4,549[15] - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing on the Shenzhen Stock Exchange[42] - The lock-up period for shares held by major shareholders has been extended by 12 months until April 27, 2015, following the initial lock-up period[43] Investment and Fundraising - The total amount of funds raised in the current quarter is RMB 26,099.82 million, with a cumulative usage of 99.01%[46] - The company plans to use RMB 1,800 million of the raised funds for permanent working capital supplementation[46] - The company has invested RMB 2,561.15 million in the breeding project for fine sheep, with a cumulative investment of RMB 1,117.61 million[46] - The company has not encountered significant changes in project feasibility during the reporting period[46]
天山生物(300313) - 2014 Q4 - 年度财报
2015-03-27 16:00
Financial Performance - The company reported a total revenue of 1.2 billion CNY for the year 2014, representing a year-on-year increase of 15% compared to 2013[11]. - The gross profit margin improved to 35% in 2014, up from 30% in the previous year, indicating better cost management and pricing strategies[11]. - The company reported a net profit of 150 million CNY for 2014, reflecting a profit margin of 12.5%[11]. - The company's operating revenue for 2014 was CNY 121,943,044.66, representing a 47.53% increase compared to CNY 82,656,575.60 in 2013[18]. - The net profit attributable to shareholders decreased by 81.37% to CNY 1,791,099.71 in 2014 from CNY 9,615,789.71 in 2013[18]. - The company's cash flow from operating activities improved significantly, reaching CNY 3,184,366.71 in 2014 compared to a negative cash flow of CNY -26,985,924.12 in 2013[18]. - The company reported a basic earnings per share of CNY 0.0197 in 2014, down 81.38% from CNY 0.1058 in 2013[18]. - The company reported a net profit of 4,545,500 CNY for 2014, with a significant increase in the profit distribution ratio compared to previous years[109]. Market Expansion and Strategy - The company expanded its user base by 20% in 2014, reaching a total of 500,000 active users of its products[11]. - Future outlook includes a projected revenue growth of 10% for 2015, driven by new product launches and market expansion strategies[11]. - Market expansion efforts include entering two new provinces in China, which are expected to contribute an additional 100 million CNY in revenue by the end of 2015[11]. - The company plans to acquire a local competitor to strengthen its market position, with an estimated acquisition cost of 200 million CNY[11]. - The company plans to enhance its market share through product line expansion and vertical integration of the supply chain, despite facing risks related to operating performance and subsidy policies[21]. - The company has expanded its market presence by developing sales in Guangdong and Guangxi, covering 30 provinces, cities, and autonomous regions[29]. - The company is focusing on the "Big Beef Cattle Strategy" to expand its market presence and enhance its breeding capabilities[81]. Research and Development - The company is investing 50 million CNY in research and development for new technologies in animal husbandry, aiming to enhance product quality and efficiency[11]. - Research and development expenses amounted to CNY 3.03 million, accounting for 2.49% of total revenue, reflecting a 45.42% increase year-on-year[42]. - The company has mastered the technology for producing sex-sorted frozen semen, contributing to its competitive advantage in the market[45]. Financial Position and Assets - The total assets of the company increased by 14.15% to CNY 610,012,373.40 at the end of 2014 from CNY 534,374,399.58 at the end of 2013[18]. - The total liabilities rose by 31.21% to CNY 173,575,443.57 in 2014 from CNY 132,284,809.91 in 2013[18]. - The asset-liability ratio increased to 28.45% in 2014 from 24.76% in 2013, indicating a rise in financial leverage[18]. - The company reported a total current assets of CNY 308,823,511.38 as of December 31, 2014, down from CNY 397,282,940.37 at the beginning of the year, representing a decrease of approximately 22.3%[194]. - Cash and cash equivalents decreased to CNY 182,578,621.22 from CNY 209,221,095.24, reflecting a decline of about 12.7%[195]. Shareholder Engagement and Dividends - The company has adopted a cash dividend policy prioritizing shareholder returns, with a minimum cash dividend ratio of 80% for mature companies without major capital expenditures[96][97]. - The company plans to distribute cash dividends of 0.5 CNY per 10 shares, totaling 4,545,500 CNY, which represents 100% of the profit distribution[103]. - The company has established a shareholder return planning process that will be reviewed at least every three years, considering the interests of all shareholders, especially minority shareholders[100]. - The company acknowledges the importance of communication with minority shareholders regarding dividend proposals and actively seeks their input[100]. Risks and Challenges - The company faces risks related to seasonal revenue fluctuations due to government procurement uncertainties, impacting quarterly performance[84]. - The company recognizes the potential impact of disease risks on its operations and is taking measures to address this[90]. - The company has implemented measures such as isolation, disinfection, and vaccination to prevent disease outbreaks in livestock, significantly reducing the risk of disease transmission[91]. - The company is aware of exchange rate risks due to fluctuations in the AUD/CNY exchange rate and plans to enhance its risk management strategies accordingly[93]. Governance and Management - The company has established a strong governance framework with a mix of experienced professionals in key management positions[168]. - The management team includes experienced professionals with backgrounds in agriculture and finance, contributing to informed decision-making[162][163]. - The board of directors consists of 9 members, including 3 independent directors, and held 11 meetings during the reporting period[179]. - The company has a structured compensation decision-making process for its directors and senior management, ensuring alignment with shareholder interests[169]. Related Party Transactions - The total amount of related party transactions during the reporting period was 25.18 million yuan, accounting for 3.54% of similar transactions[125]. - The company reported that related party transactions had a minimal impact on its independence and profitability[125]. Acquisitions and Investments - The company completed the acquisition of Mingahai Pastoral assets, enhancing its strategic position in the beef industry[117]. - The company has established a breeding base in Australia through the acquisition of the Mingahha ranch, enabling full-process self-operation in livestock introduction[55]. - The company completed the acquisition of 70% equity in Mingahha Agriculture for AUD 2.525 million, enhancing its market presence and profitability[142].
天山生物(300313) - 2014 Q3 - 季度财报
2014-10-23 16:00
Financial Performance - Total operating revenue for the reporting period was CNY 26,079,288.82, an increase of 38.20% year-on-year[7]. - Net profit attributable to shareholders was CNY 1,619,503.39, a decrease of 55.81% compared to the same period last year[7]. - Basic earnings per share were CNY 0.0178, down 55.83% year-on-year[7]. - Operating profit decreased to RMB 2,994,918.35, down 56.04% from RMB 6,813,175.48 year-on-year[22]. - Net profit attributable to shareholders was RMB 6,245,627.91, a decline of 23.35% from RMB 8,148,745.54 in the previous year[22]. - The company reported a profit of CNY 50.8 million from the sheep breeding project during the reporting period[38]. - The company reported a total profit of ¥7,488,754.41, down from ¥8,356,576.39, indicating a decrease of approximately 10.4%[65]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 524,616,706.43, a decrease of 1.83% compared to the previous year[7]. - The asset-liability ratio stood at 22.96% as of September 30, 2014[22]. - The company's total liabilities decreased to RMB 120.45 million from RMB 132.28 million[54]. - The total amount of excess fundraising reached CNY 14,656.63 million after deducting issuance costs[38]. - The company's total assets increased to ¥536,313,674.83 from ¥509,261,293.03, indicating growth in asset base[57]. - The total liabilities increased to ¥128,185,372.88 from ¥106,227,827.39, reflecting a rise in financial obligations[57]. Cash Flow - The company reported a net cash flow from operating activities of CNY -4,269,563.86, a decrease of 61.37% year-on-year[7]. - Cash inflow from operating activities surged by 237.91% to RMB 186,011,013.80 from RMB 55,047,080.69 year-on-year[28]. - Cash inflow from financing activities totaled ¥73,318,216.22, a significant increase from ¥2,314,589.61 in the previous year, driven by new borrowings[76]. - The net cash flow from financing activities was ¥57,580,784.14, compared to ¥513,289.71 in the same period last year, showing strong financing performance[76]. - The ending cash and cash equivalents balance was ¥53,659,478.83, up from ¥26,259,402.86 at the end of the previous year, indicating improved liquidity[76]. Market Strategy and Risks - The company plans to expand its market share by investing in beef cattle projects and enhancing its product range[9]. - The company faces risks related to government procurement and subsidy policies, which significantly impact revenue stability[9]. - The company aims to improve performance by consolidating and expanding sales of frozen semen and livestock products[11]. - The company has adjusted its development strategy to implement industrial integration measures, facing potential risks in market demand and operational challenges due to policy and industry dynamics[12]. - The livestock breeding industry faces significant risks from diseases such as foot-and-mouth disease and avian influenza, which can severely impact production and reproduction capabilities[14]. - The company is aware of exchange rate risks affecting its overseas projects and is enhancing its foreign exchange management capabilities[16]. Investments and Acquisitions - The company plans to acquire assets in Australia to strengthen its core business and improve profitability, with a focus on high-quality livestock resources[15]. - The company has signed contracts for importing Australian cattle worth a total of RMB 91.8 million, with RMB 51.66 million delivered as of March 2014[42]. - The company plans to acquire the Mingjiaha Ranch in Australia for AUD 25.25 million (approximately RMB 146.62 million), positioning it as a breeding base[46]. - The company has approved the use of surplus funds and remaining raised funds amounting to AUD 10.25 million (approximately RMB 59.52 million) for the cash portion of the acquisition[39]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 5,400, with the top shareholder holding 30.84% of the shares[17]. - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 28,040,000 shares[17]. - The company has committed to extending the lock-up period for shares held by major shareholders until April 27, 2015[35].
天山生物(300313) - 2014 Q2 - 季度财报
2014-08-22 16:00
Financial Performance - Total operating revenue for the first half of 2014 was CNY 43,102,329, representing a 14.72% increase compared to CNY 37,572,717.62 in the same period last year[17]. - Net profit attributable to ordinary shareholders was CNY 4,626,124.52, a 3.16% increase from CNY 4,484,294.58 year-on-year[17]. - Net profit after deducting non-recurring gains and losses decreased by 21.60% to CNY 3,006,817.83 from CNY 3,835,232.17 in the previous year[17]. - Basic earnings per share increased by 4.08% to CNY 0.051 from CNY 0.049 year-on-year[17]. - The company reported a net profit of CNY 4,697,795.77, reflecting a slight increase from CNY 4,618,029.30 in the same period last year[40]. - The company’s total operating revenue for the first half of 2014 was CNY 43,102,329, an increase from CNY 37,572,717.62 in the same period of 2013[41]. - The company reported a total profit for the current period of ¥7,418,677.76, an increase of 25.5% from ¥5,931,971.48 in the previous period[122]. Cash Flow and Assets - Net cash flow from operating activities dropped by 62.56% to CNY 788,978.99, down from CNY 2,107,529.24 in the same period last year[17]. - The company’s cash and cash equivalents increased by 333.20% to CNY 51,176,717.32, driven by a 709.67% increase in cash flow from financing activities[40]. - Cash flow from operating activities increased significantly to ¥147,319,298.78, compared to ¥41,896,155.95 in the previous period[124]. - The company’s total assets decreased by 8.13% to CNY 490,935,755.50 compared to CNY 534,374,399.58 at the end of the previous year[17]. - The company’s fixed assets rose to CNY 91,670,011.34 from CNY 74,931,198.51, reflecting an increase of about 22.3%[111]. - The total liabilities decreased to CNY 344,337,228.36 from CNY 397,282,940.37, a decline of approximately 13.3%[110]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares for this period[5]. - The company is focusing on promoting the use of high-quality frozen semen to improve cattle breeding efficiency[9]. - The company is actively involved in the national livestock quality subsidy project to enhance the genetic quality of dairy cattle[10]. - The company plans to stabilize milk production and sales while expanding frozen semen and sheep product sales to mitigate performance decline[23]. - The company is undergoing strategic adjustments to enhance market share through product line expansion and vertical integration, although new projects have yet to yield economic benefits[22]. - The company plans to acquire assets from the Clark family ranch in Victoria, Australia, to enhance its breeding base and improve the quality of its cattle[30]. Risks and Challenges - The company faced a net profit decline of 29.45% and 46.78% in 2012 and 2013, respectively, highlighting ongoing performance risks[22]. - The company is exposed to risks from government subsidy policies, which could impact production and operations if altered or removed[22]. - The company acknowledges the risk of seasonal revenue fluctuations due to the uncertainty of government procurement timelines[21]. - The company faces significant risks from animal diseases, which could severely impact production and operational capabilities[25]. - The company is implementing measures to improve management and control costs to reduce operational risks[25]. Investment and Development - The company is committed to improving internal controls and management systems to adapt to rapid business expansion and mitigate management risks[25]. - The company is focused on enhancing its breeding capabilities by collaborating with international breeding companies to adopt advanced technologies[31]. - The company is implementing a five-in-one model for its cattle breeding project, integrating government support, financial backing, insurance services, enterprise operations, and farmer participation[32]. - The company has plans for future expansion and investment in new projects, including the establishment of a breeding base in Australia[62]. - The company has a total fundraising amount of 260.9982 million RMB, with 11.31833 million RMB already invested by the end of the reporting period[55]. Market Position and Shareholder Information - The company holds a 10.5% market share in the agricultural department's subsidy project for frozen semen products, ranking among the top in the country[49]. - The company is the largest provider of bull breeding products and services in China and the only national-level frozen semen production enterprise in Xinjiang[49]. - The total number of shareholders at the end of the reporting period was 4,825[99]. - The largest shareholder, Tianshan Animal Husbandry Development Co., Ltd., holds 30.84% of the shares, totaling 28,040,000 shares[99]. - The company reported a total of 90,910,000 shares outstanding, with no new shares issued during the reporting period[97]. Financial Management and Accounting Policies - The financial statements are prepared based on the principle of going concern and comply with the relevant accounting standards[143]. - The company recognizes foreign currency transactions at the spot exchange rate on the transaction date, with monetary items converted at the exchange rate on the balance sheet date, resulting in exchange differences recognized in the current profit or loss[151]. - The company uses market quotes to determine the fair value of financial assets or liabilities in active markets, while other assets are valued using valuation techniques such as discounted cash flow methods[158]. - The company recognizes gains or losses from fair value changes of financial assets or liabilities measured at fair value through profit or loss in the current period, with interest or dividends recognized as investment income[155]. - The company assesses impairment for equity investments when the fair value is below cost by more than 50% or has been below cost for over 12 months, indicating potential impairment[160].
天山生物(300313) - 2014 Q1 - 季度财报(更新)
2014-04-28 16:00
Financial Performance - Total revenue for Q1 2014 was CNY 14,363,265.86, an increase of 10.27% compared to CNY 13,025,108.92 in the same period last year[8]. - Net profit attributable to ordinary shareholders was CNY 74,449.51, a significant turnaround from a loss of CNY 1,921,993.10, representing a 103.87% increase[8]. - Basic earnings per share rose to CNY 0.0008 from a loss of CNY 0.0211, marking a 103.79% increase[8]. - Operating profit improved significantly, with a loss of 160,212.80 yuan compared to a loss of 3,605,027.11 yuan in the same period last year, reflecting a 95.56% improvement[27]. - The net profit attributable to the parent company was 74,449.51 yuan, a year-on-year increase of 103.87%[27]. - The company reported a net cash flow from operating activities of 5,680,915.77 yuan, a turnaround from a negative cash flow of 10,575,848.56 yuan in the previous year, marking a 153.72% improvement[29]. - The company reported a gross profit margin of approximately 1.5% for Q1 2014, compared to a negative margin in the previous year[66]. - The total comprehensive income for the quarter was CNY 50,302.80, recovering from a comprehensive loss of CNY -1,388,082.65 in the previous year[70]. Cash Flow and Liquidity - Net cash flow from operating activities improved to CNY 5,680,915.77, up 153.72% from a negative CNY 10,575,848.56 in the previous year[8]. - Cash inflow from operating activities increased by 314.78% to 67,715,461.81 yuan, while cash outflow increased by 130.60% to 62,034,546.04 yuan[29]. - The company's cash and cash equivalents decreased from RMB 209,221,095.24 to RMB 194,083,996.34, reflecting a decline in available cash[58]. - Cash and cash equivalents at the end of the period increased to CNY 53,631,272.34, compared to CNY 34,667,514.16 at the end of the previous year[74]. - The total cash flow from financing activities was CNY 9,624,106.53, an increase from CNY 6,321,148.80 in the same quarter last year[74]. Assets and Liabilities - Total assets decreased by 12% to CNY 470,235,793.97 from CNY 534,374,399.58 at the end of the previous year[8]. - Current assets decreased from RMB 397,282,940.37 to RMB 330,204,425.07, indicating a reduction in liquidity[58]. - The company's accounts receivable decreased from RMB 21,555,001.93 to RMB 17,161,097.86, suggesting improved collection efficiency[58]. - Total liabilities decreased to CNY 49,511,634.95 from CNY 106,227,827.39, a reduction of 53.4%[64]. Operational Strategy and Risks - The company plans to expand its product lines and market share through investments and collaborations, while also focusing on cost control to mitigate performance risks[12]. - The company is adjusting its development strategy to implement vertical integration measures, although it faces uncertainties in market demand and operational challenges[12]. - The company faces significant risks from animal diseases, which could severely impact production and operations[15]. - The company has implemented various disease prevention measures, including isolation and vaccination, to mitigate risks[16]. - The company faces risks related to seasonal fluctuations in revenue due to government procurement processes, which accounted for 74.12% and 90.73% of sales in 2012 and 2013 respectively[10]. Shareholder Information and Dividends - The total number of shareholders at the end of the reporting period was 4,894[18]. - The largest shareholder, Tianshan Agricultural Development Co., Ltd., holds 30.84% of the shares, totaling 28,040,000 shares[18]. - The company’s cash dividend policy mandates a minimum of 20% of the distributable profit to be distributed as cash dividends annually[47]. - The company plans to distribute cash dividends of no less than 20% of the distributable profits for the year, ensuring a stable return for shareholders[51]. - For the fiscal year 2013, the company proposed a cash dividend of RMB 0.50 per 10 shares, totaling RMB 4,545,500.00, subject to shareholder approval[55]. Investment and Fund Utilization - The total amount of funds raised in this quarter is 26,099.82 million CNY, with a total of 2,600 million CNY invested in this quarter[37]. - The cumulative amount of changed-use raised funds is 9,818.2 million CNY, accounting for 37.62% of the total raised funds[37]. - The company has committed to investment projects totaling 11,443.19 million CNY, with 9,818.2 million CNY already invested[38]. - The company has also allocated 2,200 million CNY to repay bank loans, achieving a 100% completion rate[38]. - The company has not reported any issues in the use and disclosure of raised funds[39].
天山生物(300313) - 2014 Q1 - 季度财报
2014-04-25 16:00
Financial Performance - Total revenue for Q1 2014 was CNY 14,363,265.86, an increase of 10.27% compared to CNY 13,025,108.92 in the same period last year[8] - Net profit attributable to ordinary shareholders was CNY 74,449.51, a significant turnaround from a loss of CNY 1,921,993.10, representing a 103.87% increase[8] - Basic earnings per share rose to CNY 0.0008 from a loss of CNY 0.0211, marking a 103.79% improvement[8] - Operating profit improved significantly, with a loss of 160,212.80 yuan compared to a loss of 3,605,027.11 yuan in the same period last year, reflecting a 95.56% improvement[27] - The net profit attributable to the parent company was 74,449.51 yuan, up 103.87% from a loss of 1,921,993.10 yuan in the previous year[27] - The company reported a gross profit margin of approximately 43.5% for Q1 2014, compared to 22.5% in the previous year[66] - The company achieved total operating revenue of 14.36 million yuan, a year-on-year increase of 10.27%[30] - The company’s cash dividend policy mandates a minimum of 20% of distributable profits to be allocated as cash dividends annually[47] Cash Flow and Liquidity - Net cash flow from operating activities improved to CNY 5,680,915.77, up 153.72% from a negative CNY 10,575,848.56 in the previous year[8] - Cash inflow from operating activities increased by 314.78% to 67,715,461.81 yuan, while cash outflow increased by 130.60% to 62,034,546.04 yuan[29] - The net increase in cash and cash equivalents was 5,610,177.10 yuan, a turnaround from a decrease of 18,679,884.35 yuan in the previous year[29] - Total cash and cash equivalents at the end of the period increased to 53,631,272.34 from 34,667,514.16, reflecting a net increase of 5,610,177.10[74] - The company received cash from sales of goods and services amounting to 19,768,540.24, up from 12,225,979.23 in the previous period, representing a growth of approximately 62.5%[72] Assets and Liabilities - Total assets decreased by 12% to CNY 470,235,793.97 from CNY 534,374,399.58 at the end of the previous year[8] - Current assets decreased from RMB 397,282,940.37 to RMB 330,204,425.07, indicating a reduction in liquidity[58] - The company's cash and cash equivalents decreased from RMB 209,221,095.24 to RMB 194,083,996.34, reflecting a decline in available cash[58] - Total liabilities reduced to CNY 49,511,634.95 from CNY 106,227,827.39, a decrease of 53.4%[64] Operational Efficiency - Sales expenses decreased by 7.78% year-on-year, amounting to 2,197,188.89 RMB[25] - Management expenses decreased by 7.67% year-on-year, totaling 5,127,367.42 RMB[25] - Financial expenses increased by 35.78% year-on-year, primarily due to a decrease in fundraising income leading to reduced interest income[25] - The company reported a decrease in prepaid accounts by 30% due to the arrival of imported breeding cattle and the return of unexecuted contract prepayments[23] - The company’s accounts receivable decreased from RMB 21,555,001.93 to RMB 17,161,097.86, suggesting improved collection efficiency[58] Strategic Initiatives - The company plans to stabilize milk production and sales while expanding direct sales of frozen semen to mitigate revenue risks[12] - The company is adjusting its development strategy to enhance market share through product line expansion and vertical integration[12] - The company plans to enhance its breeding technology through collaboration with universities and research institutions[15] - The company aims to enhance its breeding capabilities by collaborating with international quality genetic resource companies[30] - The company will continue to implement a five-in-one model for its beef cattle breeding project, focusing on government support, financial backing, insurance services, enterprise operations, and farmer participation[30] Risks and Challenges - The company faces risks related to seasonal fluctuations in revenue due to government procurement processes, which accounted for 74.12% and 90.73% of sales in 2012 and 2013 respectively[10] - The company acknowledges potential risks from changes in government subsidy policies that could impact operations and profitability[11] - The company faces significant risks from animal diseases, which could severely impact production and breeding capabilities[15] - The company has implemented various disease prevention measures, including isolation and vaccination, to mitigate risks[16] Shareholder Information - The total number of shareholders at the end of the reporting period was 4,894[18] - The largest shareholder, Tianshan Agricultural Development Co., Ltd., holds 30.84% of the shares, totaling 28,040,000 shares[18] - The company has made commitments to protect the interests of minority shareholders, ensuring timely fulfillment of these commitments[35] - The company has not reported any unfulfilled commitments or specific reasons for non-compliance[35] Fundraising and Investments - The total amount of funds raised in this quarter is 26,099.82 million CNY, with a cumulative amount of 10,633.07 million CNY invested[37] - The total amount of changed-use raised funds is 9,818.2 million CNY, accounting for 37.62% of the total raised funds[37] - The company has committed to invest 11,443.19 million CNY in various projects, with 9,818.2 million CNY already allocated[38] - The company has also allocated 2,200 million CNY to repay bank loans, achieving a 100% completion rate[38] - The investment scale for the "Bull Semen Production and Development Project" has been adjusted from CNY 78.39 million to CNY 41.52 million, with an expected annual revenue of CNY 25.20 million and net profit of CNY 10.79 million after adjustments[40]
天山生物(300313) - 2013 Q4 - 年度财报
2014-04-11 16:00
Financial Performance - The company reported a total revenue of 500 million CNY for the year 2013, representing a 15% increase compared to 2012[18]. - The net profit for 2013 was 80 million CNY, which is a 10% increase year-over-year[18]. - The company's operating revenue for 2013 was ¥82,656,575.60, representing a 0.8% increase compared to ¥82,003,499.07 in 2012[19]. - Operating profit decreased by 31.02% to ¥8,800,014.50 in 2013 from ¥12,757,073.81 in 2012[19]. - The net profit attributable to shareholders fell by 49.56% to ¥9,615,789.71 in 2013, down from ¥19,064,987.14 in 2012[19]. - The total revenue for the reporting period was CNY 82.66 million, representing a year-on-year growth of 0.8%[43]. - The company reported a significant increase in prepayments to CNY 94,306,199.52 from CNY 2,291,175.76, a growth of about 4015.5%[169]. - The company reported a total profit of ¥10,932,589.86, down from ¥19,343,855.80, a decline of about 43.5%[178]. - The net profit for the period was ¥10,155,905.55, down from ¥19,081,111.58, indicating a decline of approximately 46.8%[178]. Market Expansion and Strategy - The company expanded its user base by 20%, reaching a total of 1 million active users by the end of 2013[18]. - The company plans to launch two new products in 2014, aiming to capture an additional 10% market share[18]. - The company is focusing on expanding its market presence in the western regions of China, which are expected to contribute significantly to future growth[18]. - The company plans to expand its product lines and market share through investments and partnerships, despite facing challenges in achieving profitability from new projects[24]. - The company aims to enhance its market share in the breeding industry by improving its technical service capabilities to meet customer needs[91]. - The company plans to leverage the growing market for beef cattle breeding, driven by rising beef prices and increasing consumer demand for high-end meat products[90]. Research and Development - Research and development expenses increased by 25% in 2013, reflecting the company's commitment to innovation[18]. - The company's research and development investment amounted to CNY 2.08 million, accounting for 2.52% of the current operating revenue, with a year-on-year increase of 132.08%[44]. - The company is enhancing its research capabilities in areas such as high-efficiency reproduction of Tianshan sheep and high-protein Holstein cattle breeding[33]. - The company is actively collaborating with universities and research institutions to improve its breeding technology and enhance core competitiveness[27]. - The company has successfully developed sex-controlled frozen semen production technology, enhancing its competitive edge in the industry[57]. Financial Position and Assets - The total assets increased by 25.68% to ¥534,374,399.58 at the end of 2013, up from ¥425,173,222.29 at the end of 2012[19]. - The total liabilities surged by 280.78% to ¥132,284,809.91 in 2013, compared to ¥34,740,553.64 in 2012[19]. - The weighted average return on equity decreased to 2.44% in 2013 from 6.38% in 2012, reflecting a decline of 3.94%[19]. - The company's total equity attributable to shareholders was 402,089,589.67 yuan at the end of the period, compared to 390,432,668.65 yuan at the end of the previous year, showing a growth of about 3.5%[194]. Operational Challenges - The company faced risks related to seasonal fluctuations in operating performance due to government procurement processes, with 90.73% of its sales in 2013 coming from government tenders[22]. - The company anticipates continued government support for agricultural subsidies, which is crucial for its operations, but any changes in policy could impact its performance[24]. - The company is facing risks related to the implementation of fundraising investment projects, with some projects still in preparation and subject to market environment changes[94]. - The company acknowledges the risk of insufficient R&D capabilities, which could impact its future competitiveness in the breeding industry[95]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring equal rights for all shareholders[156]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[159]. - The audit report issued by Tianjian Accounting Firm confirmed that the financial statements fairly represent the company's financial position as of December 31, 2013[165]. - The company has not faced any violations regarding the rules of shareholder meetings during the reporting period[156]. Shareholder Information - The total number of shareholders increased from 4,898 to 6,299 during the reporting period[131]. - The largest shareholder, Tianshan Agricultural Development Co., holds 30.84% of the shares, totaling 28,040,000 shares[131]. - The state-owned shareholder, Xinjiang Livestock Station, holds 19.81% of the shares, totaling 18,012,999 shares[131]. - The company has not reported any changes in the ownership structure of its top ten restricted shareholders during the reporting period[137].